Education · Tier 3

· Last Reviewed May 12, 2026· PSI Editorial Board· Independent

How Do I Find a Peptide Doctor Near Me?

The honest map of how to find a qualified peptide doctor through the three primary access pathways and what physician vetting requires.

Any licensed physician in the United States can prescribe peptides for a patient.

Experience with peptide therapy varies widely across practices.

Specialty match to your indication shapes which physician fits your need.

The PSI physician directory and three primary access pathways frame the search.

3 Pathways

Access Routes

Primary care, specialty practice, and telehealth as the three main access pathways

5 Cities

PSI Directory

Verified physician directory across NY, Miami, LA, Dallas, and Austin

ABMS

Certification Standard

American Board of Medical Specialties certification across relevant specialties

AMA 1.1.5

Off-Label Framework

AMA Code of Medical Ethics governs off-label and compounded prescribing decisions

Quick Answer

Any licensed physician in the United States can prescribe FDA-approved peptides and compounded peptides under AMA Code of Medical Ethics 1.1.5. Experience with peptide therapy varies widely across practices.

Three primary access pathways serve patients. The first pathway is primary care for FDA-approved indications. The second pathway is specialty practice including endocrinology, obesity medicine, and rheumatology. The third pathway is telehealth through state-licensed physicians operating in your state of residence.

Physician vetting includes state medical board license verification, ABMS board certification, and peptide experience verification. The American Board of Obesity Medicine is one relevant subspecialty for weight management. Endocrinology serves Semaglutide and Tirzepatide for type 2 diabetes. Endocrinology and rheumatology serve Teriparatide, Abaloparatide, and Romosozumab for osteoporosis.

Specialty match by indication shapes which physician fits your need. Weight management indication aligns with primary care or obesity medicine. Type 2 diabetes indication aligns with primary care or endocrinology. High fracture risk osteoporosis indication aligns with endocrinology or rheumatology.

The PSI physician directory provides verified physicians across major US cities. Telehealth physicians must hold an active license in your state of residence. The DEA Ryan Haight Act of 2008 imposes additional telehealth controlled substance prescribing requirements.

For specific guidance, see Do I Need a Doctor for Peptides and How Physicians Recommend Peptides. Also see Compounded vs FDA-Approved Peptides and Red Flags in Peptide Prescribing.

Three primary access pathways serve patients seeking peptide therapy in the United States. The first pathway runs through primary care for FDA-approved indications like weight management and type 2 diabetes. The second pathway involves specialty practice including endocrinology, obesity medicine, rheumatology, and sports medicine depending on indication. The third pathway is telehealth through licensed physicians operating in your state of residence. Physician vetting includes state medical board license verification, board certification status, peptide experience verification, and indication match. The PSI physician directory provides verified physicians across major US cities. Discuss with primary care first for FDA-approved indication routing.

WHICH PATHWAY?

At a Glance: Finding a Peptide Doctor

Patient Scenario	Subtitle	Animal Evidence	Human Evidence	Recommended Pathway
Adult seeking FDA-approved weight management peptide	Primary care or obesity medicine specialty	—	Strong	Primary care for Wegovy or Zepbound prescribing; obesity medicine specialty for complex weight cases
Adult seeking type 2 diabetes peptide therapy	Primary care or endocrinology	—	Strong	Primary care for routine Ozempic or Mounjaro; endocrinology for complex glycemic management
Adult with high fracture risk osteoporosis	Endocrinology or rheumatology specialty	—	Strong	Endocrinology or rheumatology for Forteo, Tymlos, or Evenity per AACE/Endo Society guidelines
Adult seeking growth hormone deficiency evaluation	Endocrinology specialty	—	Strong	Endocrinology for adult-onset GHD evaluation with insulin tolerance test or glucagon stimulation
Adult considering compounded peptide pathway	Physician with 503A or 503B pharmacy familiarity	—	Moderate	Specialty practice with compounded peptide experience and pharmacy verification capability
Adult preferring telehealth access for FDA-approved peptide	Telehealth platform with state-licensed physicians	—	Moderate	Telehealth physician licensed in your state with FDA-approved peptide prescribing capability
Adult in rural area with limited specialty access	Telehealth or specialty consultation with primary care coordination	—	Moderate	Telehealth specialty consultation with primary care as ongoing prescribing physician
Adult evaluating direct-to-consumer peptide marketing claims	Licensed physician evaluation required	—	Limited	Direct-to-consumer marketing claims should route through licensed physician evaluation before any therapy decision

Six Things You Need to Know About Finding a Peptide Doctor

This page covers how to find a qualified peptide doctor in the United States. The framework spans six sections. Section one defines what a peptide doctor is under federal and state law. Section two covers the three primary access pathways. Section three details physician vetting framework. Section four addresses specialty match by indication. Section five covers telehealth-specific considerations. Section six lists red flags in physician selection.

Any Licensed Physician Can Prescribe Peptides, But Experience Varies

United States federal and state law allow any licensed physician to prescribe FDA-approved peptides for FDA-approved indications and to prescribe off-label or compounded peptides under AMA Code of Medical Ethics 1.1.5. Practical experience with peptide therapy varies widely across practices.

Federal and state law in the United States permit any licensed physician with an active state medical license and DEA registration where applicable to prescribe FDA-approved peptides for FDA-approved indications. Off-label prescribing of FDA-approved peptides is legal under AMA Code of Medical Ethics 1.1.5 with documented informed consent. Compounded peptide prescribing through 503A pharmacies or 503B outsourcing facilities is legal with physician due diligence on pharmacy quality. The legal framework does not require a specific peptide certification or peptide specialty board. The American Board of Medical Specialties does not currently offer a peptide-specific subspecialty certification. Practical experience with peptide therapy varies widely. Primary care physicians who prescribe Wegovy or Ozempic routinely for FDA-approved indications have substantial experience. Endocrinologists, obesity medicine specialists, rheumatologists, and sports medicine physicians often have deeper experience with specialty-specific peptide therapy. Practices that offer compounded peptide programs vary in pharmacy verification and AMA Code 1.1.5 informed consent documentation. Patients should evaluate physician experience through indication match, board certification, peptide therapy track record, and specialty coordination capability.

Three Primary Access Pathways Serve Patients in the United States

Three primary access pathways frame peptide doctor selection. The pathways are primary care, specialty practice, and telehealth. Each pathway has appropriate use cases by indication and patient context.

Primary care is the first access pathway. Primary care physicians prescribe FDA-approved peptides like Wegovy, Ozempic, Saxenda, and Victoza routinely for FDA-approved indications including chronic weight management and type 2 diabetes. Primary care can coordinate referrals to specialty practice when complex indications or compounded peptide pathways apply. Specialty practice is the second access pathway. Endocrinology serves type 2 diabetes, growth hormone deficiency, and complex metabolic cases. Obesity medicine (American Board of Obesity Medicine certified) serves complex chronic weight management cases. Rheumatology serves osteoporosis cases requiring Forteo, Tymlos, or Evenity per AACE and Endocrine Society guidelines. Sports medicine and orthopedics may serve tissue repair peptide research interests. Sexual health specialists or urologists may serve PT-141 and related research compound interests. Telehealth is the third access pathway. Telehealth physicians operate under state medical licenses and DEA registrations applicable to the patient's state of residence. Telehealth supports FDA-approved peptide prescribing for established indications and follow-up care. Telehealth limitations apply to initial controlled substance prescribing, certain compounded peptide pathways, and complex specialty coordination. Discuss with primary care or specialty practice about which access pathway fits your indication and clinical context.

Physician Vetting Framework Covers License, Certification, Experience, and Coordination

Physician vetting for peptide therapy follows a structured framework. The framework includes state medical board license verification, ABMS board certification status, peptide therapy experience verification, and specialty coordination capability.

State medical board license verification is the foundation of physician vetting. Every state medical board provides online license verification through the state medical board portal. The verification confirms the physician holds an active and unrestricted license in the state where they practice. License lookup confirms disciplinary history and any restrictions. The American Board of Medical Specialties certification is the second framework element. ABMS verification through certificationmatters.org confirms the physician holds current board certification in their primary specialty. Board certification verifies the physician has completed accredited residency, passed specialty board examinations, and maintains continuing medical education requirements. The American Board of Obesity Medicine is one relevant subspecialty certification for weight management peptide therapy. The Endocrine Society and American Association of Clinical Endocrinology provide guideline frameworks for endocrinology-specific peptide therapy. Peptide therapy experience verification is the third element. Patients can ask about case volume, indication-specific experience, pharmacy verification practices for compounded peptide work, and AMA Code 1.1.5 informed consent documentation practices. Specialty coordination capability is the fourth element. Complex peptide therapy cases benefit from multi-specialty coordination across primary care, endocrinology, rheumatology, weight medicine, sports medicine, and sexual health specialists. The PSI physician directory provides verified physicians who meet license, certification, and peptide experience benchmarks.

Specialty Match by Indication Shapes Which Physician Fits Your Need

Different peptide therapy indications align with different specialty disciplines. Specialty match is one of the most important factors in physician selection because peptide therapy is indication-driven rather than peptide-category-driven.

Weight management indication matches primary care or American Board of Obesity Medicine certified physicians for FDA-approved Wegovy, Saxenda, or Zepbound prescribing. Type 2 diabetes with cardiovascular risk indication matches primary care or endocrinology for FDA-approved Ozempic, Victoza, or Mounjaro with ADA Standards of Care 2024 framework. High fracture risk osteoporosis indication matches endocrinology or rheumatology for FDA-approved Forteo, Tymlos, or Evenity per AACE/ACE 2020 CPG (Camacho et al.) and Endocrine Society 2019 CPG (Eastell et al.). Adult-onset growth hormone deficiency matches endocrinology for FDA-approved Sermorelin, Tesamorelin (Egrifta), or somatropin therapy with insulin tolerance test or glucagon stimulation test confirmation. HIV-associated lipodystrophy matches infectious disease or endocrinology with FDA-approved Tesamorelin (Egrifta) pathway. Sexual health and erectile dysfunction indications match urology or sexual medicine specialists for compounded PT-141 (bremelanotide) research consideration. Tissue repair and recovery indications match sports medicine or orthopedics for compounded BPC-157 research consideration, with clear understanding of evidence limitations. Immune support indications match infectious disease or primary care for compounded thymosin research consideration. The indication-driven specialty match approach prevents the misconception that any peptide can be approached through any specialty. Patients should consult primary care first for indication assessment and specialty referral.

Telehealth Pathway Has Specific Capabilities and Regulatory Constraints

Telehealth peptide therapy operates under specific regulatory constraints. Capabilities include FDA-approved peptide prescribing for established indications. Constraints include state licensing requirements, certain DEA controlled substance limitations, and complex specialty coordination needs.

Telehealth physicians must hold an active medical license in the state of the patient's residence. The licensing requirement is not optional and is enforced through state medical boards. The DEA Ryan Haight Online Pharmacy Consumer Protection Act of 2008 imposes additional requirements on telehealth controlled substance prescribing including in-person evaluation requirements for new patient relationships. The DEA has issued temporary flexibilities since the COVID-19 public health emergency that have shifted multiple times. Patients pursuing telehealth peptide therapy should verify the physician's state licensure for the patient's state and confirm the prescribing capability for the specific peptide under consideration. Telehealth capabilities include FDA-approved peptide prescribing for established indications like Wegovy, Ozempic, Zepbound, and Mounjaro. Telehealth is appropriate for established patient-physician relationships, follow-up care, dose titration, and medication management within indication. Telehealth limitations include initial controlled substance prescribing under DEA Ryan Haight requirements, certain compounded peptide pathways requiring pharmacy verification, and complex specialty coordination needs that benefit from in-person evaluation. The PSI directory includes physicians with telehealth practice operating within these regulatory frameworks. Discuss with telehealth physician about state licensure, prescribing capabilities for your indication, and specialty coordination if needed.

Red Flags in Peptide Doctor Selection Apply to Marketing, Pricing, and Quality Practices

Red flags in peptide doctor selection signal practices that operate outside validated clinical frameworks. The flags fall in three categories: marketing claims, pricing structures, and quality practices.

Marketing-based red flags include direct-to-consumer marketing claiming peptide therapy can address indications without FDA-approved peptide alternatives, claims of proprietary or signature peptide programs, claims of guaranteed outcomes with peptide therapy, marketing of compounded peptides as equivalent to FDA-approved peptides, and absence of physician-patient relationship before prescribing. Pricing-based red flags include flat-fee programs that bypass individualized clinical evaluation, programs that require payment for peptide therapy independent of clinical assessment, package deals that bundle peptide therapy with unrelated services, and aggressive sales tactics during clinical evaluation. Quality-based red flags include absence of state medical board license verification, absence of ABMS board certification, absence of AMA Code 1.1.5 informed consent documentation for off-label or compounded prescribing, absence of pharmacy verification for compounded peptide prescriptions, absence of monitoring protocols for ongoing therapy, and absence of specialty coordination capability for complex cases. The defensive posture is to verify the physician operates within validated clinical practice frameworks. Patients should consult primary care or specialty practice about any red flag observed during physician selection. The PSI physician directory provides verified physicians who meet license, certification, and peptide experience benchmarks while operating within the AMA Code of Medical Ethics framework.

Primary care vs specialty practice vs telehealth as three access pathways

How the three primary access pathways differ in scope, capability, and patient context

Primary care physicians prescribe FDA-approved peptides routinely for FDA-approved indications. Wegovy and Saxenda for chronic weight management. Ozempic and Victoza for type 2 diabetes with cardiovascular benefit. Zepbound and Mounjaro for chronic weight management and type 2 diabetes per the ADA 2024 Standards of Care framework. Primary care can coordinate referrals to specialty practice when complex indications or compounded peptide pathways apply. Insurance coverage is generally established for FDA-approved indications through primary care prescribing with prior authorization. Primary care is the default first-line access pathway for FDA-approved peptide therapy.

Specialty practice provides deeper expertise for indication-specific peptide therapy. Endocrinology serves type 2 diabetes, growth hormone deficiency, and complex metabolic cases including adult GHD evaluation with insulin tolerance or glucagon stimulation testing. Obesity medicine (American Board of Obesity Medicine certified) serves complex chronic weight management cases with multi-modal therapy coordination. Rheumatology serves high fracture risk osteoporosis cases requiring Forteo (teriparatide NDA 021318), Tymlos (abaloparatide), or Evenity (romosozumab NDA 761062 with cardiovascular boxed warning) per AACE/ACE 2020 and Endocrine Society 2019 CPG frameworks. Specialty practice is appropriate for complex indications and multi-specialty coordination.

Telehealth pathway operates under specific regulatory frameworks. Telehealth physicians must hold an active state medical license in the patient's state of residence. The DEA Ryan Haight Online Pharmacy Consumer Protection Act of 2008 imposes additional requirements on telehealth controlled substance prescribing. Telehealth supports FDA-approved peptide prescribing for established indications including follow-up care and dose titration. Telehealth limitations include certain initial controlled substance prescribing and complex specialty coordination needs. Telehealth is appropriate for established patient-physician relationships and ongoing care within indication.

Specialty match by indication: how to choose the right physician discipline

Indication-driven specialty selection across weight management, diabetes, osteoporosis, GHD, and sexual health

Weight management indication aligns with primary care or American Board of Obesity Medicine certified physicians. Type 2 diabetes indication aligns with primary care or endocrinology. The ADA 2024 Standards of Care identifies GLP-1 receptor agonists like semaglutide (Ozempic) and dual incretin agonists like tirzepatide (Mounjaro) as recommended therapies for type 2 diabetes with cardiovascular risk reduction (Lincoff et al. SELECT NEJM 2023, Marso et al. SUSTAIN-6).

High fracture risk osteoporosis indication aligns with endocrinology or rheumatology. The AACE/ACE 2020 CPG (Camacho et al.) and Endocrine Society 2019 CPG (Eastell et al.) recommend bone-forming peptides Forteo (teriparatide), Tymlos (abaloparatide), or Evenity (romosozumab with cardiovascular boxed warning) for postmenopausal women at high fracture risk. Forteo Phase 3 demonstrated approximately 65 percent vertebral fracture reduction. Evenity FRAME demonstrated 73 percent vertebral fracture reduction.

Adult-onset growth hormone deficiency indication aligns with endocrinology for FDA-approved Sermorelin, Tesamorelin (Egrifta) for HIV-associated lipodystrophy, or somatropin therapy with insulin tolerance test or glucagon stimulation test confirmation per the AACE 2019 GHD CPG framework.

Sexual health and erectile dysfunction indications may align with urology or sexual medicine specialists for compounded PT-141 (bremelanotide) research consideration with clear evidence limitations. Tissue repair and recovery indications may align with sports medicine or orthopedics for compounded BPC-157 research consideration with documented informed consent per AMA Code 1.1.5. Immune support indications may align with infectious disease or primary care for compounded thymosin research consideration. Indication-driven specialty selection prevents the misconception that any peptide can route through any specialty.

Physician vetting framework: license, certification, experience, and coordination

Four-element vetting framework for any peptide doctor selection

State medical board license verification is the foundation. Every state medical board provides online license verification through the state medical board portal. The verification confirms the physician holds an active and unrestricted license in the state where they practice. License lookup confirms disciplinary history and any restrictions. The Texas Medical Board, California Department of Consumer Affairs, New York State Education Department, and Florida Department of Health are examples of state-level licensing authorities with online verification.

American Board of Medical Specialties (ABMS) board certification verification is the second framework element. ABMS verification through certificationmatters.org confirms the physician holds current board certification in their primary specialty. The American Board of Obesity Medicine certification is one relevant subspecialty for weight management peptide therapy. The American Board of Internal Medicine endocrinology subspecialty certification is relevant for type 2 diabetes and GHD evaluation. The American Board of Internal Medicine rheumatology subspecialty certification is relevant for osteoporosis peptide therapy.

Peptide therapy experience verification is the third element. Patients can ask about case volume for the specific indication, peptide-specific experience including FDA-approved and compounded peptide work, pharmacy verification practices for any compounded peptide prescriptions, and AMA Code 1.1.5 informed consent documentation practices. Specialty coordination capability is the fourth element. Complex peptide therapy cases benefit from multi-specialty coordination across primary care, endocrinology, rheumatology, weight medicine, sports medicine, and sexual health specialists. The PSI physician directory provides verified physicians who meet license, certification, and peptide experience benchmarks.

In-person versus telehealth peptide doctor: regulatory and clinical comparison

How in-person and telehealth pathways compare in regulatory framework, clinical capability, and patient fit

In-person peptide therapy through primary care or specialty practice provides direct physical examination, in-office bloodwork ordering through the practice, direct pharmacy coordination including compounded peptide pathway verification, and multi-specialty coordination including direct specialist referrals. In-person pathway is appropriate for initial peptide therapy evaluation, complex cases requiring physical examination, controlled substance prescribing requiring DEA Ryan Haight Act compliance, and complex compounded peptide pathway coordination.

Telehealth peptide therapy operates under the patient's state of residence licensing requirement. Telehealth physicians must hold an active state medical license in the patient's state. Telehealth supports FDA-approved peptide prescribing for established indications, follow-up care, dose titration, and medication management within indication. Telehealth is appropriate for established patient-physician relationships, ongoing FDA-approved peptide therapy, and patients in rural areas with limited specialty access. The DEA Ryan Haight Online Pharmacy Consumer Protection Act of 2008 governs telehealth controlled substance prescribing.

The choice between in-person and telehealth depends on indication complexity, patient access, insurance coverage, and physician availability. Specialty coordination strengthens decisions for complex cases. Patients should consult primary care or specialty practice about which pathway fits the specific clinical context. See [Telehealth vs In-Person Peptide Prescriptions](/education/telehealth-vs-in-person-peptide-prescriptions) for the detailed comparison framework.

Research Suggests

Direction

Finding a qualified peptide doctor in the United States operates through three access pathways with a four-element vetting framework.

Three primary access pathways serve patients seeking peptide therapy: primary care for FDA-approved indications, specialty practice for indication-specific expertise, and telehealth for patients within state licensing frameworks. The four-element vetting framework includes state medical board license verification, ABMS board certification status, peptide therapy experience verification, and specialty coordination capability. Specialty match by indication shapes physician selection. The PSI physician directory provides verified physicians across major US cities operating within validated clinical practice frameworks per AMA Code of Medical Ethics 1.1.5 and 2.1.1.

Strongest evidence

Primary care for FDA-approved peptide prescribing within indication has the strongest evidence and most established access pathway.

Primary care physicians prescribing FDA-approved peptides for FDA-approved indications operate within the strongest framework. Wegovy and Saxenda for chronic weight management. Ozempic and Victoza for type 2 diabetes with cardiovascular benefit. Zepbound and Mounjaro for chronic weight management and type 2 diabetes per ADA Standards of Care 2024. Forteo, Tymlos, and Evenity for high fracture risk osteoporosis per AACE/ACE 2020 and Endocrine Society 2019 CPGs. Primary care prescribing follows FDA prescribing information for each FDA-approved product. Insurance coverage is generally established with prior authorization. The pathway carries the strongest regulatory, clinical, and access foundation.

Limitations

Compounded peptide prescribing and complex specialty coordination require deeper physician vetting and specific framework adherence.

Compounded peptide pathways require physician verification of pharmacy quality assurance including state pharmacy board license (503A) or FDA registration (503B), PCAB accreditation, USP Chapter 797 and 800 compliance, and third-party testing practices. Off-label use of FDA-approved peptides requires documented informed consent per AMA Code of Medical Ethics 1.1.5. Telehealth controlled substance prescribing operates under the DEA Ryan Haight Online Pharmacy Consumer Protection Act of 2008 with state licensing requirements. Direct-to-consumer marketing claims should route through licensed physician evaluation before any therapy decision. Patients should consult primary care or specialty practice for individualized clinical context.

Assessment

Match physician specialty to indication. Verify license, certification, and experience. Use the PSI physician directory for vetted physicians.

PSI's reading: physician selection for peptide therapy should follow indication-driven specialty match through one of the three primary access pathways with the four-element vetting framework applied. Weight management routes through primary care or obesity medicine. Type 2 diabetes routes through primary care or endocrinology. High fracture risk osteoporosis routes through endocrinology or rheumatology. Adult-onset GHD routes through endocrinology. Compounded peptide pathways require physician familiarity with 503A or 503B pharmacy verification frameworks. Telehealth requires verified state licensure for the patient's state of residence and DEA Ryan Haight Act compliance for controlled substance prescribing. The PSI physician directory provides verified physicians across major US cities. Anyone bypassing license verification, ABMS board certification verification, AMA Code 1.1.5 informed consent documentation, or pharmacy verification for compounded prescribing is operating outside the validated clinical framework.

How to Approach Your Decision

Limitations and Caveats

Any licensed physician with active state medical license and applicable DEA registration can prescribe FDA-approved peptides for FDA-approved indications. Peptide-specific certification is not currently offered by the American Board of Medical Specialties.
Specialty match by indication shapes physician selection. Weight management aligns with primary care or obesity medicine. Type 2 diabetes aligns with primary care or endocrinology. Osteoporosis aligns with endocrinology or rheumatology. Adult-onset GHD aligns with endocrinology.
Physician vetting requires state medical board license verification through the state board portal. License lookup confirms active and unrestricted status, disciplinary history, and any restrictions.
ABMS board certification verification through certificationmatters.org confirms current specialty board certification. The American Board of Obesity Medicine is one relevant subspecialty for weight management peptide therapy.
Telehealth physicians must hold an active state medical license in the patient's state of residence. The DEA Ryan Haight Online Pharmacy Consumer Protection Act of 2008 imposes additional requirements on telehealth controlled substance prescribing.
Compounded peptide pathways require physician verification of pharmacy quality assurance. Verification includes 503A state pharmacy board license, 503B FDA registration, PCAB accreditation, USP 797 and 800 compliance, and third-party testing practices.
Off-label use of FDA-approved peptides requires documented informed consent per AMA Code 1.1.5. Patients can request copies of informed consent documentation for transparency.
The PSI physician directory provides verified physicians across major US cities. Verification covers state license, ABMS board certification, peptide therapy experience, and AMA Code 1.1.5 documentation practices.

What's Marketed vs What's Studied

7 common claims, corrected.

“There is a specific peptide doctor specialty I need to find.”

The American Board of Medical Specialties does NOT currently offer a peptide-specific subspecialty certification. Peptide therapy is indication-driven: weight management aligns with primary care or obesity medicine, type 2 diabetes with primary care or endocrinology, osteoporosis with endocrinology or rheumatology, growth hormone deficiency with endocrinology, and so on. The right physician matches your indication, not a generic peptide specialty.

“Only a peptide clinic or specialty wellness practice can prescribe peptides.”

Any licensed physician in the United States with an active state medical license can prescribe FDA-approved peptides for FDA-approved indications, and can prescribe off-label or compounded peptides under AMA Code of Medical Ethics 1.1.5 with documented informed consent. Primary care physicians prescribe Wegovy, Ozempic, Zepbound, and Mounjaro routinely for FDA-approved indications. A specialty clinic is not the legal prerequisite.

“Telehealth peptide doctors can prescribe anything anywhere in the country.”

Telehealth physicians must hold an active state medical license in the PATIENT'S state of residence, not just where the physician is based. The DEA Ryan Haight Online Pharmacy Consumer Protection Act of 2008 imposes additional requirements on telehealth controlled substance prescribing including in-person evaluation requirements for new patient relationships. Telehealth has real regulatory boundaries.

“A physician on a peptide marketing website is automatically vetted.”

Marketing websites do not perform physician vetting. Patients should independently verify state medical board license through the state board portal, ABMS board certification through certificationmatters.org, peptide therapy experience for the specific indication, and AMA Code 1.1.5 informed consent documentation practices. The PSI physician directory performs independent vetting with documented verification standards.

“Board certification is not important for peptide therapy.”

American Board of Medical Specialties certification verifies the physician completed accredited residency, passed specialty board examinations, and maintains continuing medical education requirements. Board certification is one of the strongest indicators of clinical competence within a specialty. For weight management, American Board of Obesity Medicine certification is a relevant subspecialty. For endocrinology and rheumatology, American Board of Internal Medicine subspecialty certifications apply.

“My primary care doctor will not understand peptide therapy.”

Primary care physicians prescribe FDA-approved peptides routinely for FDA-approved indications. Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, and Victoza are commonly prescribed in primary care. For complex indications or compounded peptide pathways, primary care can coordinate specialty referrals. Starting with primary care for indication assessment is the appropriate first step in most peptide therapy decisions.

“A flat-fee peptide program represents efficient access.”

Flat-fee programs that bundle peptide prescribing with package pricing can bypass individualized clinical evaluation, indication-specific assessment, and AMA Code 1.1.5 informed consent documentation. Quality clinical practice prices clinical evaluation independently from medication. Patients should be cautious about programs that require payment for peptide therapy independent of clinical assessment, package deals bundling unrelated services, or aggressive sales tactics during evaluation.

Common Questions

How do I find a peptide doctor near me?

Start with three primary access pathways: primary care for FDA-approved indications, specialty practice for indication-specific expertise (endocrinology, obesity medicine, rheumatology), and telehealth for established patient-physician relationships within state licensing frameworks. The PSI physician directory provides verified physicians across major US cities. Match physician specialty to your indication: weight management to primary care or obesity medicine; type 2 diabetes to primary care or endocrinology; osteoporosis to endocrinology or rheumatology.

What specialty is best for peptide therapy?

There is no single specialty for peptide therapy. The right specialty depends on the indication. Weight management aligns with primary care or American Board of Obesity Medicine certified physicians. Type 2 diabetes aligns with primary care or endocrinology. High fracture risk osteoporosis aligns with endocrinology or rheumatology per AACE/ACE 2020 and Endocrine Society 2019 CPGs. Adult-onset growth hormone deficiency aligns with endocrinology. Sexual health may align with urology or sexual medicine.

Does the American Board of Medical Specialties offer peptide certification?

No. The American Board of Medical Specialties does not currently offer a peptide-specific subspecialty certification. ABMS subspecialties that are relevant to peptide therapy include the American Board of Obesity Medicine for weight management, American Board of Internal Medicine endocrinology subspecialty for type 2 diabetes and GHD, American Board of Internal Medicine rheumatology subspecialty for osteoporosis, and similar specialty certifications by indication.

Can my primary care doctor prescribe peptide therapy?

Yes. Any licensed physician in the United States with an active state medical license can prescribe FDA-approved peptides for FDA-approved indications. Primary care physicians prescribe Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, and Victoza routinely for FDA-approved weight management and type 2 diabetes indications. Primary care can also coordinate specialty referrals for complex indications or compounded peptide pathways.

What is the American Board of Obesity Medicine?

The American Board of Obesity Medicine (ABOM) is a subspecialty certification for physicians focused on chronic weight management. ABOM-certified physicians have completed additional training and passed the ABOM examination demonstrating expertise in obesity medicine. ABOM certification is one relevant credential for chronic weight management peptide therapy including Wegovy, Saxenda, and Zepbound prescribing. ABOM certification is voluntary but indicates focused expertise.

How do I verify a physician's state medical license?

Every state medical board provides online license verification. Examples include the Texas Medical Board, California Department of Consumer Affairs, New York State Education Department physician license verification, and Florida Department of Health. The verification confirms the physician holds an active and unrestricted license in the state where they practice. License lookup also shows disciplinary history and any restrictions.

How do I verify ABMS board certification?

ABMS board certification verification is available through certificationmatters.org. The verification confirms the physician holds current board certification in their primary specialty including continuing medical education compliance. Board certification verifies completion of accredited residency training and passing of specialty board examinations. Certification status is one of the strongest indicators of clinical competence within a specialty.

Can a telehealth physician prescribe peptides?

Yes, telehealth physicians can prescribe FDA-approved peptides for established indications. Telehealth physicians must hold an active state medical license in the PATIENT'S state of residence. The DEA Ryan Haight Online Pharmacy Consumer Protection Act of 2008 imposes additional requirements on telehealth controlled substance prescribing including in-person evaluation requirements for new patient relationships. Telehealth is appropriate for established patient-physician relationships, follow-up care, and ongoing FDA-approved peptide therapy.

What is the DEA Ryan Haight Act?

The DEA Ryan Haight Online Pharmacy Consumer Protection Act of 2008 governs telehealth controlled substance prescribing in the United States. The Act generally requires in-person physician evaluation before controlled substance prescribing through telehealth, with specific exceptions. The DEA has issued temporary flexibilities since the COVID-19 public health emergency that have shifted multiple times. Telehealth physicians prescribing controlled substances must operate within current DEA framework.

What questions should I ask before choosing a peptide doctor?

Key questions include: Are you licensed in my state? Are you board certified? What is your experience with peptide therapy for my specific indication? Do you prescribe FDA-approved peptides, compounded peptides, or both? For compounded prescribing, which pharmacies do you use and what verification do you require? Do you document informed consent per AMA Code 1.1.5? Do you coordinate with my primary care or other specialists for ongoing care?

Are concierge or wellness clinics good for peptide therapy?

Concierge and wellness clinics vary widely in clinical framework adherence. Patients should verify the same physician vetting framework regardless of practice setting: state medical board license, ABMS board certification, indication-specific experience, and AMA Code 1.1.5 informed consent documentation. Red flags include flat-fee programs bypassing individualized clinical evaluation, claims of proprietary peptide programs, and absence of pharmacy verification for compounded prescribing.

Does insurance cover peptide doctor visits?

Insurance coverage for peptide doctor visits depends on the specialty, indication, insurance plan, and whether the practice accepts insurance. Primary care visits are generally covered with co-pays. Specialty visits may require referrals depending on plan. FDA-approved peptide prescriptions for FDA-approved indications generally have coverage with prior authorization. Compounded peptide prescriptions are typically not covered. Verify coverage with your insurance plan before any appointment.

Should I see a primary care doctor or specialist for peptide therapy?

Start with primary care for indication assessment and FDA-approved peptide routing. Primary care can prescribe Wegovy, Ozempic, Zepbound, or Mounjaro for FDA-approved indications routinely. For complex indications including high fracture risk osteoporosis, adult-onset growth hormone deficiency, complex glycemic management, or compounded peptide pathways, specialty referral is appropriate. Specialty coordination strengthens complex decisions across primary care and specialty practice.

What is the PSI physician directory?

The PSI physician directory provides verified physicians across major US cities (NY, Miami, LA, Dallas, Austin). Directory verification includes state medical board license, ABMS board certification, peptide therapy experience for relevant indications, and AMA Code 1.1.5 informed consent documentation practices. The directory does not include direct-to-consumer peptide marketing platforms. PSI verification is independent and applies the same five-gate standard across all directory physicians.

What red flags should I watch for when choosing a peptide doctor?

Red flags include direct-to-consumer marketing without physician-patient relationship, claims that compounded peptides are equivalent to FDA-approved, flat-fee programs bypassing individualized clinical evaluation, absence of state medical board license verification, absence of ABMS board certification, absence of AMA Code 1.1.5 informed consent documentation for off-label or compounded prescribing, absence of pharmacy verification for compounded prescribing, and aggressive sales tactics during clinical evaluation. See [Red Flags in Peptide Prescribing](/education/red-flags-in-peptide-prescribing).

Do I need an endocrinologist for GLP-1 receptor agonist therapy?

Not necessarily. Primary care physicians prescribe GLP-1 receptor agonists like Ozempic, Wegovy, Mounjaro, and Zepbound routinely for FDA-approved indications. Endocrinology referral is appropriate for complex glycemic management, type 1 diabetes context, multiple comorbidities, GLP-1 receptor agonist tolerability issues, or specific specialty coordination needs. Primary care is the appropriate starting point for most patients seeking FDA-approved GLP-1 receptor agonist therapy.

What is the difference between obesity medicine and weight loss medicine?

American Board of Obesity Medicine (ABOM) certification covers chronic disease management of obesity per evidence-based clinical practice frameworks. Weight loss medicine as a marketed term is not standardized and may refer to various practice settings including cosmetic, wellness, or chronic disease management contexts. ABOM-certified physicians follow evidence-based obesity medicine frameworks including FDA-approved peptide prescribing (Wegovy, Saxenda, Zepbound) per FDA labeling and ADA Standards of Care.

How do I find a peptide doctor in a rural area?

Rural patients have three options: local primary care for FDA-approved peptide indications, telehealth physicians licensed in the patient's state of residence for established patient-physician relationships, or specialty consultation through telehealth with primary care as ongoing prescribing physician. The DEA Ryan Haight Act applies to telehealth controlled substance prescribing. Specialty coordination with primary care strengthens complex decisions even when in-person specialty access is limited.

Sourcing Checklist

Match physician specialty to your indication before choosing a peptide doctor.
Weight management aligns with primary care or American Board of Obesity Medicine. Type 2 diabetes aligns with primary care or endocrinology. Osteoporosis aligns with endocrinology or rheumatology. Adult-onset GHD aligns with endocrinology. Indication-driven matching is the first filter.
Verify the physician holds an active and unrestricted state medical license.
Every state medical board provides online license verification. Confirm the physician's license is active, unrestricted, and current in the state where they practice. License lookup also shows disciplinary history and any restrictions.
Verify ABMS board certification through certificationmatters.org.
Board certification confirms the physician completed accredited residency, passed specialty board examinations, and maintains continuing medical education. Certification status is one of the strongest indicators of clinical competence within a specialty.
Verify peptide therapy experience for the specific indication.
Ask about case volume for the indication, FDA-approved versus compounded peptide experience, and specialty coordination capability for complex cases. Indication-specific experience is more relevant than generic peptide volume.
For telehealth physicians, verify active state license in your state of residence.
Telehealth physicians must hold an active medical license in the PATIENT'S state of residence, not just where the physician is based. The DEA Ryan Haight Act of 2008 imposes additional requirements on telehealth controlled substance prescribing.
For compounded peptide prescribing, verify physician pharmacy verification practices.
Ask which 503A pharmacies or 503B outsourcing facilities the physician uses, what verification practices apply (state license, FDA registration, PCAB accreditation, USP 797/800, third-party testing), and whether they provide pharmacy verification documentation.
Verify AMA Code of Medical Ethics 1.1.5 informed consent documentation practices.
AMA Code 1.1.5 governs off-label and compounded prescribing. Confirm the physician documents risk-benefit assessment, alternatives considered (including FDA-approved options), and patient understanding. Patients can request copies of informed consent documentation.
Verify specialty coordination capability for complex cases.
Complex peptide therapy cases benefit from coordination across primary care, endocrinology, rheumatology, weight medicine, sports medicine, and sexual health specialists. Confirm the physician coordinates with primary care or other specialists when appropriate.
Watch for red flags including marketing claims, flat-fee programs, and missing verification.
Direct-to-consumer marketing without physician-patient relationship, flat-fee programs bypassing individualized clinical evaluation, absence of license or board certification verification, absence of AMA Code 1.1.5 documentation, and aggressive sales tactics during clinical evaluation are all red flags.

Regulatory Context

State medical board licensing, ABMS board certification, the DEA Ryan Haight Online Pharmacy Consumer Protection Act of 2008 framework, AMA Code of Medical Ethics 1.1.5 and 2.1.1, and FDA Compounding Quality Act state and federal frameworks all evolve over time. The DEA has issued temporary flexibilities for telehealth controlled substance prescribing since the COVID-19 public health emergency with multiple framework shifts. State medical board telehealth licensing has evolved with state-specific interstate compact frameworks like the Interstate Medical Licensure Compact. American Board of Obesity Medicine certification standards update periodically. State pharmacy board oversight of 503A compounding evolves with state-specific inspection cadences and adverse event reporting requirements. FDA 503B registration frameworks continue to refine with each guidance cycle. PSI tracks regulatory and certification changes and updates this page per the Editorial Standards review cadence. Discuss with primary care or specialty practice for current state-specific licensing and DEA requirements applicable to your specific clinical context.

Comparison

Specialty	Best Match Indications	Key Certifications	Pathway Notes
Primary Care	FDA-approved peptides for weight management, type 2 diabetes, established indications	ABMS Family Medicine or Internal Medicine	Default first-line access for FDA-approved peptide therapy
Obesity Medicine	Complex chronic weight management, multi-modal therapy coordination	American Board of Obesity Medicine (ABOM)	Subspecialty referral from primary care for complex weight cases
Endocrinology	Type 2 diabetes, GHD, complex metabolic, osteoporosis hormone framework	ABIM Endocrinology subspecialty	Adult GHD evaluation requires ITT or glucagon stimulation testing
Rheumatology	High fracture risk osteoporosis, autoimmune conditions	ABIM Rheumatology subspecialty	Forteo, Tymlos, Evenity per AACE/ACE 2020 and Endocrine Society 2019 CPG
Sports Medicine	Tissue repair research consideration, athletic performance context	ABMS Sports Medicine subspecialty	Compounded BPC-157 research with informed consent per AMA Code 1.1.5
Urology / Sexual Medicine	Erectile dysfunction, sexual health	ABMS Urology or Sexual Medicine certification	PT-141 research consideration with documented informed consent
Infectious Disease	HIV-associated lipodystrophy, immune support context	ABIM Infectious Disease subspecialty	Tesamorelin (Egrifta) FDA-approved for HIV-associated lipodystrophy
Telehealth	FDA-approved peptide follow-up, established patient relationships	Underlying specialty certification + state licensure	DEA Ryan Haight Act compliance for controlled substance prescribing

Who This Applies To

· Adult considering peptide therapy and evaluating which physician specialty fits the indication.
· Adult with FDA-approved weight management indication considering primary care or American Board of Obesity Medicine certified physician.
· Adult with type 2 diabetes considering primary care for FDA-approved Ozempic or Mounjaro or endocrinology for complex glycemic management.
· Adult with high fracture risk osteoporosis considering endocrinology or rheumatology for Forteo, Tymlos, or Evenity prescribing.
· Adult with suspected growth hormone deficiency seeking endocrinology evaluation with ITT or glucagon stimulation testing.
· Adult considering telehealth peptide therapy and verifying state licensure plus DEA Ryan Haight Act framework.
· Adult evaluating compounded peptide pathway and verifying physician pharmacy verification practices.
· Adult in rural area seeking telehealth or specialty consultation with primary care coordination.
· Patient verifying state medical board license, ABMS board certification, and peptide therapy experience.
· Patient evaluating direct-to-consumer peptide marketing claims and routing through licensed physician evaluation.

Verdict

Any licensed physician in the United States can prescribe FDA-approved peptides for FDA-approved indications. Peptide therapy is indication-driven rather than peptide-specialty-driven. The right physician depends on your specific indication. Weight management routes to primary care or American Board of Obesity Medicine certified physicians. Type 2 diabetes routes to primary care or endocrinology. High fracture risk osteoporosis routes to endocrinology or rheumatology. Adult-onset growth hormone deficiency routes to endocrinology. Sexual health may route to urology or sexual medicine. The four-element vetting framework applies regardless of pathway. The first element is state medical board license verification. The second is ABMS board certification verification through certificationmatters.org. The third is peptide therapy experience for the specific indication. The fourth is specialty coordination capability. Telehealth physicians must hold an active state medical license in the patient's state of residence. The DEA Ryan Haight Act of 2008 imposes additional requirements on telehealth controlled substance prescribing. Compounded peptide pathways require physician verification of pharmacy quality assurance. Off-label use of FDA-approved peptides requires documented informed consent per AMA Code 1.1.5. Direct-to-consumer marketing should route through licensed physician evaluation. The PSI physician directory provides verified physicians across major US cities operating within validated clinical practice frameworks.

In Plain Terms

Any doctor with a license can prescribe peptides in the United States. Experience varies a lot between practices. The right doctor depends on what you want to treat. Weight management routes to primary care or an obesity medicine specialist. Type 2 diabetes routes to primary care or an endocrinologist. Bone problems route to endocrinology or rheumatology. Hormone issues route to endocrinology. Sexual health may route to urology. To pick a good doctor, check four things. The first is the state medical license through the state board website. The second is board certification through certificationmatters.org. The third is experience with your specific condition. The fourth is whether they coordinate with other doctors when needed. The PSI directory lists doctors we have already checked. Telehealth doctors need a license in YOUR state, not just theirs.

You do not need a special peptide doctor. Any licensed doctor in the United States can prescribe FDA-approved peptides like Wegovy, Ozempic, Zepbound, or Mounjaro. The trick is matching the doctor to your condition. For weight loss, primary care or an obesity doctor works. For diabetes, primary care or an endocrinologist works. For weak bones, endocrinology or rheumatology. For growth hormone issues, endocrinology. Before booking, look the doctor up on the state medical board website to make sure their license is active. Then check certificationmatters.org to see if they have current board certification. Ask them how much experience they have with peptide therapy for your situation. If you want telehealth, the doctor needs a license in your state, not theirs. The PSI directory is a list of doctors we already checked.

For any peptide therapy consideration, physician selection through the four-element vetting framework is the legal and clinical gate. PSI maintains a vetted directory of practitioners with peptide experience operating within validated clinical practice frameworks including primary care, telehealth, endocrinology, weight medicine, rheumatology, and other specialties per AMA Code of Medical Ethics 1.1.5 + state medical board licensing + ABMS board certification standards.

Find a verified physician

PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.

Browse the directory Learn about the verification process →

Related Conditions

Related Education

Featured Compounds

Common Contexts

· Adult finding primary care physician for Wegovy or Zepbound prescribing for chronic weight management
· Adult finding primary care or endocrinology for Ozempic or Mounjaro prescribing for type 2 diabetes
· Adult finding endocrinology or rheumatology for Forteo, Tymlos, or Evenity prescribing for osteoporosis
· Adult finding endocrinology for adult-onset GHD evaluation with ITT or glucagon stimulation testing
· Adult finding American Board of Obesity Medicine certified physician for complex chronic weight management
· Adult finding telehealth physician licensed in their state of residence for FDA-approved peptide follow-up
· Adult finding physician with 503A or 503B pharmacy verification capability for compounded peptide pathway
· Adult verifying state medical board license through state board portal before scheduling appointment
· Adult verifying ABMS board certification through certificationmatters.org before scheduling appointment
· Adult evaluating direct-to-consumer peptide marketing claims through licensed physician evaluation

Important Context

This page is educational and does not constitute medical advice. The information presented reflects state medical board licensing frameworks, American Board of Medical Specialties certification standards, the DEA Ryan Haight Online Pharmacy Consumer Protection Act of 2008, AMA Code of Medical Ethics 1.1.5 and 2.1.1, ADA 2024 Standards of Care, AACE/ACE and Endocrine Society guidelines, and FDA prescribing information for FDA-approved peptides as referenced.

Your physician will evaluate your specific clinical context, indication match, insurance coverage, FDA-approved alternatives, and personal preferences when developing your peptide therapy plan. The framework described here is general and does not substitute for individualized clinical judgment. Specialty coordination strengthens complex decisions across primary care and specialty practice.

Educational content only. Discuss with your physician before pursuing any peptide therapy pathway. Physician vetting should include state medical board license verification, ABMS board certification status, peptide therapy experience verification, and AMA Code 1.1.5 informed consent documentation for off-label or compounded prescribing decisions.

Sources and Citations

[1] FDA Prescribing Information: Wegovy (semaglutide) injection 2.4 mg · 2024 · FDA NDA 215256 · Source
[2] FDA Prescribing Information: Ozempic (semaglutide) injection · 2024 · FDA NDA 209637 · Source
[3] FDA Prescribing Information: Zepbound (tirzepatide) injection · 2024 · FDA NDA 217806 · Source
[4] FDA Prescribing Information: Forteo (teriparatide) injection · 2020 · FDA NDA 021318 · Source
[5] FDA Prescribing Information: Evenity (romosozumab-aqqg) injection with cardiovascular boxed warning · 2019 · FDA NDA 761062 · Source
[6] FDA Prescribing Information: Egrifta (tesamorelin) injection for HIV-associated lipodystrophy · 2024 · FDA NDA 022505 · Source
[7] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial) · New England Journal of Medicine · 2023 · DOI
[8] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) · New England Journal of Medicine · 2022 · DOI
[9] Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) · New England Journal of Medicine · 2016 · DOI
[10] AMA Code of Medical Ethics Opinion 1.1.5: Off-label and Investigational Use of Pharmaceuticals · American Medical Association · 2024 · Source
[11] AMA Code of Medical Ethics Opinion 2.1.1: Informed Consent · American Medical Association · 2024 · Source
[12] American Diabetes Association. Standards of Care in Diabetes 2024 · Diabetes Care · 2024 · DOI
[13] Camacho PM, Petak SM, Binkley N, et al. AACE/ACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2020 Update · Endocrine Practice · 2020 · DOI
[14] Eastell R, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline · Journal of Clinical Endocrinology and Metabolism · 2019 · DOI
[15] AACE Adult Growth Hormone Deficiency Clinical Practice Guidelines for Diagnosis and Treatment · Endocrine Practice · 2019
[16] DEA Ryan Haight Online Pharmacy Consumer Protection Act of 2008: Telehealth controlled substance prescribing framework · US Drug Enforcement Administration · 2008 · Source
[17] American Board of Medical Specialties: Board certification framework and verification through certificationmatters.org · American Board of Medical Specialties · 2024 · Source

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.